Aimable Nahimana
Lausanne, VD, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myeloma.
Journal: Blood advances
Published: April 17, 2024
Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer.
Journal: European journal of medicinal chemistry
Published: January 10, 2023
Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies.
Journal: Molecules (Basel, Switzerland)
Published: December 12, 2022
Nicotinaldehyde, a Novel Precursor of NAD Biosynthesis, Abrogates the Anti-Cancer Activity of an NAD-Lowering Agent in Leukemia.
Journal: Cancers
Published: November 15, 2022
Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: May 30, 2022
Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer.
Journal: European journal of medicinal chemistry
Published: February 02, 2022
Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia.
Journal: Cell death & disease
Published: June 22, 2021
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1.
Journal: Autophagy
Published: February 26, 2021
Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH.
Journal: Drug metabolism letters
Published: October 04, 2018
Activation of Bone Marrow-Derived Cells Angiotensin (Ang) II Type 1 Receptor by Ang II Promotes Atherosclerotic Plaque Vulnerability.
Journal: International journal of molecular sciences
Published: August 02, 2018
Last Updated: 09/26/2026